Tuesday, August 1, is World Lung Cancer Day. Raise awareness and hope for the 2M people diagnosed with lung cancer worldwide each year. Be a part

About Lung Cancer | Diagnosis | Types

Small Cell Lung Cancer

Lung cancer is the number one cancer killer worldwide.

Of the 220,000 new cases diagnosed each year, Small Cell Lung Cancer (SCLC) accounts for 15% of cases. As an aggressive form of lung cancer, better therapies are needed desperately.

SCLC Research Update

New Treatment for Small Cell Lung Cancer

Dr. Sands and Maida emphasize the critical role of innovative therapies and clinical trials in transforming small cell lung cancer care, encouraging patients to explore all available options for the best outcomes.

What is Small Cell Lung Cancer, and why is it so tough to treat?

Small cell lung cancer is one of the two major types of lung cancer – the other type being non-small cell lung cancer. SCLC is an uncontrolled proliferation of small cells in the lung. In contrast, NSCLC occurs in non-small cells like glandular cells in the case of adenocarcinoma, or squamous cells, like in squamous cell carcinoma. About 15% of all lung cancer cases are classified as SCLC, also known as oat cell cancer, and usually presents more aggressively than NSCLC.

There are a few factors that contribute to the difficulty in treating SCLC. Since lung cancer screening is generally uncommon and symptoms usually don’t present themselves until the later stages, patients don’t know that they have SCLC until it’s more difficult to treat. And once the diagnosis is known, the disease is particularly problematic because the particular mutations in SCLC suppress the natural mechanism our cells have to stop uncontrolled cell growth.

Although SCLC initially responds well to standard treatment protocol, aggressive chemotherapy, it usually has only short-term effects. It is not long before the disease returns and is even faster growing than before treatment. The life expectancy for a patient diagnosed with SCLC is under one year.

Learn about the SCLC research underway

These are grim and frightening statistics. The good news is that the scientific world is giving more attention to SCLC now than ever before. Research, both in the lab and clinical trials, has led to the most significant strides in treatment in the past 30 years. Scientists are gaining a deeper understanding of the disease which can result in discovering new treatment options.

Seek out the many clinical trials currently underway across the US

Dr. Lovly and Dr. Rudin encourage patients to learn more about options for finding a trial that may be right for them.

FDA-Approved Treatments for Small Cell Lung Cancer

Types
  • Tarlatamab-dlle (Imdelltra)

    Tarlatamab is given to small cell lung cancer patients who have already tried chemotherapy but whose cancer has come back or spread.

    This injectable medicine is an antibody that targets a protein on cancer cells called DLL3. By attaching to DLL3, tarlatamab helps the body’s immune system find and destroy the cancer cells. In a clinical trial, some patients who received tarlatamab had their tumors shrink or disappear for some time.

    Approved for: SCLC

    Biomarkers: SCLC

    FDA Approval Date: 05/16/2024

    Used in: SCLC

  • Nivolumab (Opdivo/Opdivo Injection)

    Nivolumab (Opdivo/Opdivo Injection) is a FDA-approved CombinationTherapy for Small cell lung cancer (SCLC) that has metastasized. It is used in patients whose cancer got worse after treatment with platinum chemotherapy and at least one other therapy.

    Approved for: SCLC

    Biomarkers: SCLC

    FDA Approval Date: 08/01/2018

    Used in: SCLC

  • Lurbinectedin (Zepzelca)

    Small cell lung cancer that is metastatic. It is used in adults whose disease has gotten worse during or after treatment with platinum chemotherapy. *This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that lurbinectedin provides a clinical benefit in these patients.*

    Approved for: SCLC

    Biomarkers: SCLC

    FDA Approval Date: 07/16/2024

    Used in: SCLC

  • Pembrolizumab (Keytruda)

    Small cell lung cancer that has metastasized. It is used in patients whose disease got worse during or after treatment with platinum chemotherapy and at least one other therapy.

    Approved for: SCLC

    Biomarkers: SCLC

    FDA Approval Date: 03/01/2020

    Used in: Immunotherapy

  • Etoposide

    Small cell lung cancer. It is used with other chemotherapy as first-line treatment.

    Approved for: SCLC

    Biomarkers: SCLC

    FDA Approval Date: 07/16/2024

    Used in: SCLC

  • Carboplatin (Paraplatin)

    Carboplatin + paclitaxel (carbo taxol) is given to shrink tumors and improve symptoms of lung cancer. If the disease is not metastatic (spread to areas of the body outside the lungs), carboplatin + paclitaxel may be given as first line adjuvant or neoadjuvant therapy with the goal of cure.

    Approved for: NSCLC, SCLC

    Biomarkers: SCLC

    FDA Approval Date: 07/16/2024

    Used in: SCLC

  • Topotecan Hydrochloride (Hycamtin)

    Small cell lung cancer in patients whose disease has not gotten better with other chemotherapy.

    Approved for: SCLC

    Biomarkers: SCLC

    FDA Approval Date: 07/16/2024

    Used in: SCLC

Screening is No Small Matter

The earlier lung cancer is detected, the more treatment options are available to you. Hear from Dusty and Maida about the importance of getting screened.